menu search

TBPH / Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return

Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return
Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initiate a large capital return and launch a strategic review. Read More
Posted: May 3 2023, 04:45
Author Name: Seeking Alpha
Views: 111014

TBPH News  

Theravance: Positive Findings Boost Ampreloxetine Development

By Seeking Alpha
September 9, 2023

Theravance: Positive Findings Boost Ampreloxetine Development

Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's fina more_horizontal

Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold

By Seeking Alpha
September 8, 2023

Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold

Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation fo more_horizontal

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

By PRNewsWire
August 28, 2023

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new amprel more_horizontal

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

By Zacks Investment Research
August 8, 2023

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year. more_horizontal

Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 7, 2023

Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Call Transcript

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Exec more_horizontal

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 7, 2023

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to more_horizontal

Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return

By Seeking Alpha
May 3, 2023

Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return

Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initi more_horizontal

Theravance Biopharma to Participate in an Upcoming Investor Conference

By PRNewsWire
April 10, 2023

Theravance Biopharma to Participate in an Upcoming Investor Conference

DUBLIN , April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conferenc more_horizontal


Search within

Pages Search Results: